| abstract |
The present invention relates to pharmaceutical products comprising a combination of: (i) a MET inhibitor, and (ii) an epidermal growth factor receptor (EGFR) inhibitor, or a pharmaceutically acceptable salt thereof, respectively, or a pro-drug thereof, which are jointly active in the treatment of proliferative diseases; to the corresponding pharmaceutical formulations, to the uses, methods, processes, commercial packages, and related embodiments of the invention. |